From Bitcoin miner to AI landlord: Can MARA Holdings, Inc. unlock 2.5GW of power-backed upside?
MARA Holdings, Inc. partners with Starwood to build 2.5GW of AI-ready data centers. See how this pivot could reshape its valuation and strategy.
How Brink’s Company’s $6.6bn NCR Atleos acquisition reshapes global ATM infrastructure
Brink’s Company to acquire NCR Atleos Corporation for $6.6B. Discover how the deal reshapes global ATM infrastructure and recurring revenue strategy.
Rocket Lab Corporation (Nasdaq: RKLB) strengthens vertical integration in space optics with Tucson acquisition
Rocket Lab Corporation (Nasdaq: RKLB) acquires Optical Support, Inc. to strengthen defense payload integration. Discover what this means for growth and margins.
Will Omega Products International become Cemex’s blueprint for capital-efficient U.S. expansion?
Cemex S.A.B. de C.V. is acquiring Omega Products International in a sub-7x EBITDA deal. Explore the margin, synergy, and U.S. growth implications. Read more.
Vox Royalty Corp. expands New South Wales footprint with low-cost Federation gold royalty acquisition
Vox Royalty Corp. acquires a producing gold royalty in Australia. Discover how this low-cost deal could boost cash flow and copper optionality.
How Eureka Lithium Corp.’s Stairway Mining deal reshapes its exploration strategy beyond lithium
Eureka Lithium Corp. secures 100% of Cabin Lake and Tyee projects. Discover how this critical minerals pivot could reshape its growth strategy.
Can Future Fuels Inc. build scale in Saskatchewan uranium through HUC deal?
Future Fuels Inc. expands in the Athabasca Basin with Hatchet Uranium Corp. acquisition. Discover what this means for uranium strategy and investors.
From power hog to grid hero: Can Super Micro Computer, Inc. monetize AI load flexibility?
Can AI data centers become grid assets? Explore how Super Micro Computer, CPower, and Bentaus are reshaping energy markets today.
Stability data and strategy: PharmAla Biotech Holdings Inc. builds commercial groundwork for LaNeo MDMA
PharmAla Biotech Holdings Inc. launches a three-year stability program for LaNeo MDMA. Discover how this could reshape psychedelic drug commercialization.
Johnson & Johnson strengthens oncology delivery strategy with EU nod for subcutaneous amivantamab
EU approves subcutaneous amivantamab for EGFR lung cancer. Discover how this could reshape oncology workflows and Johnson & Johnson’s strategy.